45 results on '"Dileep KV"'
Search Results
2. Quinazolinone-Hydrazine Cyanoacetamide Hybrids as Potent Multitarget-Directed Druggable Therapeutics against Alzheimer's Disease: Design, Synthesis, and Biochemical, In Silico, and Mechanistic Analyses.
- Author
-
Yelamanda Rao K, Chandran R, Dileep KV, Gorantla SC, Jeelan Basha S, Mothukuru S, Siva Kumar I, Vamsi K, Kumar S, Reddy ABM, Subramanyam R, and Damu AG
- Subjects
- Humans, Acetamides pharmacology, Acetamides chemical synthesis, Acetamides chemistry, Drug Design, Butyrylcholinesterase metabolism, Butyrylcholinesterase drug effects, Neuroprotective Agents pharmacology, Neuroprotective Agents chemical synthesis, Neuroprotective Agents chemistry, Amyloid beta-Peptides metabolism, Molecular Dynamics Simulation, Computer Simulation, Molecular Docking Simulation, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, Quinazolinones pharmacology, Quinazolinones chemistry, Quinazolinones chemical synthesis, Hydrazines pharmacology, Hydrazines chemistry, Hydrazines chemical synthesis
- Abstract
The discovery of effective multitarget-directed ligands (MTDLs) against multifactorial Alzheimer's disease (AD) remnants has been focused in an incessant drug discovery pursuit. In this perception, the current study explores the rational design, synthesis, and evaluation of 26 quinazolinone-hydrazine cyanoacetamide hybrids 7(a-j) , 8(a-j) , and 9(a-f) as MTDLs against AD. These new compounds were synthesized in four-step processes using simple phthalimide as the starting material without any major workup procedures and were characterized by different spectroscopic techniques. In Ellman's assay, the most potent analogues 7i , 8j , and 9d were identified as selective and mixed-type inhibitors of hAChE. Furthermore, biophysical and computational assessments revealed that the analogues 7i , 8j , and 9d were bound to both the catalytic active site and peripheral anionic site of hAChE with high affinity. The molecular dynamics simulation analysis highlighted the conformational changes of hAChE upon binding of 7i , 8j , and 9d and also the stability of resulting biomolecular systems all over 100 ns simulations. In addition to antioxidant activity, the most active congeners were found to protect substantially SK-N-SH cells from oxidative damage. Decisively, the most active analogues 7i , 8j , and 9d were assessed as potent Aβ
1-42 fibril modulators and protective agents against Aβ1-42 -induced toxicity in SH-SY5Y cells. Additionally, glioblastoma C6 cell-based assays also demonstrated the use of the most active congeners 7i , 8j , and 9d as protective agents against Aβ1-42 -induced toxicity. Overall, this multifunctional capacity of quinazolinone-hydrazine cyanoacetamide hybrids demonstrated the noteworthy potential of these hybrids to develop as effectual MTDLs against AD. However, further pharmacokinetics, toxicology, and behavioral studies are warranted.- Published
- 2024
- Full Text
- View/download PDF
3. Carboxylic acid derivatives suppress the growth of Aspergillus flavus through the inhibition of fungal alpha-amylase.
- Author
-
Hima S, Remya C, Sadasivan C, and Dileep KV
- Subjects
- Molecular Docking Simulation, alpha-Amylases, Monosaccharides metabolism, Monosaccharides pharmacology, Carboxylic Acids metabolism, Carboxylic Acids pharmacology, 2,4-Dichlorophenoxyacetic Acid metabolism, 2,4-Dichlorophenoxyacetic Acid pharmacology, Aspergillus flavus metabolism, Aflatoxins
- Abstract
Aspergillus favus ( A. flavus ) is a saprophytic fungus and a pathogen affecting several important foods and crops, including maize. A. flavus produces a toxic secondary metabolite called aflatoxin. Alpha-amylase (α-amylase), a hydrolytic enzyme produced by A. Flavus helps in the production of aflatoxin by hydrolysing the starch molecules in to simple sugars such as glucose and maltose. These simple sugars induce the production of aflatoxin. Inhibition of α-amylase has been proven as a potential way to reduce the production of aflatoxin. In the present study, we investigated the effect of selected carboxylic acid derivatives such as cinnamic acid (CA), 2, 4-dichlorophenoxyacetic acid (2,4-D), and 3-(4-hydroxyphenyl)-propionic acid (3,4-HPPA) on the fungal growth and for the α-amylase inhibitory activity. The binding potentials of these compounds with α-amylase have been confirmed by enzyme kinetics and isothermal titration calorimetry. Molecular docking and MD simulation studies were also performed to deduce the atomic level interaction between the protein and selected ligands. The results indicated that CA, 2,4-D and 3,4-HPPA can inhibit the fungal growth which could be partly due to the inhibition on fungal α-amylase activity.Communicated by Ramaswamy H. Sarma.
- Published
- 2024
- Full Text
- View/download PDF
4. Unveiling the molecular basis of lobeline's allosteric regulation of NMDAR: insights from molecular modeling.
- Author
-
Remya C, Variyar EJ, Omkumar RV, Sadasivan C, and Dileep KV
- Subjects
- Humans, Molecular Docking Simulation, Allosteric Regulation, Receptors, N-Methyl-D-Aspartate metabolism, Models, Molecular, Lobeline, Quality of Life
- Abstract
Neurological and psychiatric disorders contribute significantly to the global disease burden, adversely affecting the quality of life for both patients and their families. Impaired glutamatergic signaling is considered to be a major cause for most of the neurological and psychiatric disorders. Glutamate receptors are over activated in excitotoxic conditions, leading to dysregulation of Ca
2+ homeostasis, triggering the production of free radicals and oxidative stress, mitochondrial dysfunction and eventually cell death. Excitotoxicity primarily results from the overactivity of NMDARs, a subtype of ionotropic glutamate receptors, due to their pronounced Ca2+ permeability and conductance characteristics. NMDAR antagonists are suggested to have therapeutic use as they can prevent excitotoxicity. Our previous studies demonstrated lobeline, an alkaloid, exerts neuroprotective action in excitotoxic conditions by blocking NMDAR. However, the atomic level interactions of lobeline with NMDAR was not characterized yet. Structural comparison of lobeline with a known NMDAR antagonist ifenprodil, followed by molecular docking and dynamics simulations revealed that lobeline could bind to the ifenprodil binding site i.e., in the heterodimer interface of GluN1-GluN2B subunits and exert ifenprodil like activities. By in silico structure guided modifications on lobeline and subsequent free energy calculations, we propose putative NMDAR antagonists derived from lobeline., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
5. Lobeline: A multifunctional alkaloid modulates cholinergic and glutamatergic activities.
- Author
-
Remya C, Dileep KV, Variyar EJ, Omkumar RV, and Sadasivan C
- Subjects
- Rats, Animals, Lobeline pharmacology, Lobeline therapeutic use, Acetylcholinesterase chemistry, Acetylcholinesterase metabolism, Acetylcholinesterase therapeutic use, Donepezil pharmacology, Donepezil therapeutic use, Cholinesterase Inhibitors pharmacology, Cholinesterase Inhibitors chemistry, Molecular Docking Simulation, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, Alkaloids pharmacology, Alkaloids therapeutic use, Antineoplastic Agents therapeutic use, Neuroprotective Agents pharmacology
- Abstract
Developing drugs for Alzheimer's disease (AD) is an extremely challenging task due to its devastating pathology. Previous studies have indicated that natural compounds play a crucial role as lead molecules in the development of drugs. Even though, there are remarkable technological advancements in the isolation and synthesis of natural compounds, the targets for many of them are still unknown. In the present study, lobeline, a piperidine alkaloid has been identified as a cholinesterase inhibitor through chemical similarity assisted target fishing method. The structural similarities between lobeline and donepezil, a known acetylcholinesterase (AChE) inhibitor encouraged us to hypothesize that lobeline may also exhibit AChE inhibitory properties. It was further confirmed by in silico, in vitro and biophysical studies that lobeline could inhibit cholinesterase. The binding profiles indicated that lobeline has a higher affinity for AChE than BChE. Since excitotoxicity is one of the major pathological events associated with AD progression, we also investigated the neuroprotective potential of lobeline against glutamate mediated excitotoxicity in rat primary cortical neurons. The cell based NMDA receptor (NMDAR) assay with lobeline suggested that neuroprotective potential of lobeline is mediated through the blockade of NMDAR activity., (© 2023 International Union of Biochemistry and Molecular Biology.)
- Published
- 2023
- Full Text
- View/download PDF
6. Acetazolamide responsive early-onset absence epilepsy and ataxia in a toddler with a KCNA2 genetic variant; a case report.
- Author
-
Balaram N, Jose J, Gafoor A, Balachandran S, Saritha F, Dileep KV, and Balan S
- Subjects
- Humans, Child, Preschool, Ataxia, Kv1.2 Potassium Channel genetics, Acetazolamide therapeutic use, Epilepsy, Absence drug therapy, Epilepsy, Absence genetics
- Abstract
Competing Interests: Declaration of Competing Interest All authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
7. 2D finger-printing and molecular docking studies identified potent mosquito repellents targeting odorant binding protein 1.
- Author
-
Liggri PGV, Pérez-Garrido A, Tsitsanou KE, Dileep KV, Michaelakis A, Papachristos DP, Pérez-Sánchez H, and Zographos SE
- Subjects
- Female, Animals, DEET, Molecular Docking Simulation, Odorants, Mosquito Vectors, Printing, Three-Dimensional, Insect Repellents pharmacology, Aedes metabolism
- Abstract
Personal protection measures against the mosquitoes like the use of repellents constitute valuable tools in the effort to prevent the transmission of vector-borne diseases. Therefore, the discovery of novel repellent molecules which will be effective at lower concentrations and provide a longer duration of protection remains an urgent need. Mosquito Odorant-Binding Proteins (OBPs) involved in the initial steps of the olfactory signal transduction cascade have been recognized not only as passive carriers of odors and pheromones but also as the first molecular filter to discriminate semiochemicals, hence serving as molecular targets for the design of novel pest control agents. Among the three-dimensional structures of mosquito OBPs solved in the last decades, the OBP1 complexes with known repellents have been widely used as reference structures in docking analysis and molecular dynamics simulation studies for the structure-based discovery of new molecules with repellent activity. Herein, ten compounds known to be active against mosquitoes and/or displaying a binding affinity for Anopheles gambiae AgamOBP1 were used as queries in an in silico screening of over 96 million chemical samples in order to detect molecules with structural similarity. Further filtering of the acquired hits on the basis of toxicity, vapor pressure, and commercial availability resulted in 120 unique molecules that were subjected to molecular docking studies against OBP1. For seventeen potential OBP1-binders, the free energy of binding (FEB) and mode of interaction with the protein were further estimated by molecular docking simulations leading to the selection of eight molecules exhibiting the highest similarity with their parental compounds and favorable energy values. The in vitro determination of their binding affinity to AgamOBP1 and the evaluation of their repellent activity against female Aedes albopictus mosquitoes revealed that our combined ligand similarity screening and OBP1 structure-based molecular docking successfully detected three molecules with enhanced repellent properties. A novel DEET-like repellent with lower volatility (8.55 × 10
-4 mmHg) but a higher binding affinity for OBP1 than DEET (1.35 × 10-3 mmHg). A highly active repellent molecule that is predicted to bind to the secondary Icaridin (sIC)-binding site of OBP1 with higher affinity than to the DEET-site and, therefore, represents a new scaffold to be exploited for the discovery of binders targeting multiple OBP sites. Finally, a third potent repellent exhibiting a high degree of volatility was found to be a strong DEET-site binder of OBP1 that could be used in slow-release formulations., (Copyright © 2023 Elsevier Ltd. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
8. Sub-pocket-focused designing of tacrine derivatives as potential acetylcholinesterase inhibitors.
- Author
-
Babu A, John M, Liji MJ, Maria E, Bhaskar SJ, Binukmar BK, Sajith AM, Reddy EK, Dileep KV, and Sunil K
- Subjects
- Humans, Cholinesterase Inhibitors chemistry, Cholinesterase Inhibitors pharmacology, Cholinesterase Inhibitors therapeutic use, Acetylcholinesterase chemistry, Acetylcholinesterase metabolism, Acetylcholinesterase therapeutic use, Molecular Docking Simulation, Structure-Activity Relationship, Tacrine pharmacology, Tacrine therapeutic use, Alzheimer Disease metabolism
- Abstract
Human acetylcholinesterase (hAChE) has a potential role in the management of acetylcholine, one of the neurotransmitters that modulate the overall activity of cholinergic system, AChE inhibitors have a greater impact in the therapeutics. Though the atomic structure of hAChE has been extensively studied, the precise active site geometry upon binding to different ligands are yet to be explored. In the present study, an extensive structural analysis of our recently reported hAChE-tacrine complex has carried out and revealed the presence of two prominent sub-pockets located at the vicinity of the hAChE active site. Structural bioinformatics assisted studies designed 132 putative sub-pockets focused tacrine derivatives (SPFTDs), their molecular docking, free energy estimations revealed that they are stronger than tacrine in terms of binding affinity. Our in vitro studies also supported the in silico findings, all these SPFTDs are having better potencies than tacrine. Cytotoxic nature of these SPFTDs on HepG2 and Neuro-2a cell lines, diminishes the possibilities for future in vivo studies. However, the identification of these sub pockets and the SPFTDs paved a new way to the future drug discovery especially since AChE is one of the promising and approved drug targets in treatment of AD drug discovery., Competing Interests: Declaration of competing interest The authors have no conflicts of interest to disclose., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Structural analysis and ensemble docking revealed the binding modes of selected progesterone receptor modulators.
- Author
-
Saritha F, Aiswarya N, Aswath Kumar R, and Dileep KV
- Subjects
- Pregnancy, Female, Humans, Quality of Life, Receptors, Progesterone chemistry, Receptors, Progesterone metabolism, Leiomyoma drug therapy
- Abstract
Uterine fibroids (UF) are benign smooth muscle neoplasm of uterus that have a significant impact on a woman's quality of life as they perturb hormonal homeostasis resulting in heavy menstrual bleeding, impaired fertility, pregnancy complications and loss. UF can be surgically removed through invasive procedures, but their recurrence rate is often high. Progesterone receptor (PR) has an imperative role in UF management. Mifepristone, ulipristal acetate (UPA) and asoprisnil (ASO) are some selective progesterone receptor modulators (SPRMs), acts on PR, but due to their side effects in long term use, they were withdrawn from the market. Hence, there is a dire need for novel, highly efficient with least side effects, therapeutics for the treatment of UF. To contribute toward the drug discovery for UF, we made an extensive structural comparison of reported PR crystal structures, also elucidated the binding modes of four existing SPRMs against human PR through ensemble docking approach. Our studies revealed the presence of 5 highly repeating water molecules that has an important role in ligand binding and structural stability. Our ensemble docking and MD simulation revealed that studied ligands have preferential selectivity toward the specific conformation of PR. It is anticipated that our study will be a useful resource to all the drug discovery scientists who are engaged in the identification of lead molecules against UF.
- Published
- 2023
- Full Text
- View/download PDF
10. Binding of rosmarinic acid curcumin and capsaicin with PLA2: A comparative study.
- Author
-
Aiswarya N, Remya C, Remashree AB, Sadasivan C, and Dileep KV
- Subjects
- Capsaicin, Cinnamates, Depsides, Phospholipases A2 metabolism, Rosmarinic Acid, Curcumin chemistry, Curcumin pharmacology
- Abstract
Phospholipase A2 (PLA2) is a key enzyme involved in the formation of pro-inflammatory mediators like eicosanoids. Inhibition of PLA2 is regarded as one of the effective methods of controlling inflammation. The present study investigated the binding potentials of three natural compounds, rosmarinic acid (RA), capsaicin (CAP), and curcumin (CUR) by means of in silico and in vitro methods. Our study revealed that RA has relatively better binding affinity and inhibition potentials when compared to the other two molecules. Our ITC experiments were also suggested a slightly better binding energy for the RA. The stoichiometry of the protein ligand complex obtained from one of the ITC experiments suggested the possibilities of binding of a small molecule MCW (degraded product of CUR) on PLA2. Overall study demonstrated that the anti-inflammatory activity of RA, CUR and CAP may be partly due to the inhibition of PLA2., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this study., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. Crystal structure of human acetylcholinesterase in complex with tacrine: Implications for drug discovery.
- Author
-
Dileep KV, Ihara K, Mishima-Tsumagari C, Kukimoto-Niino M, Yonemochi M, Hanada K, Shirouzu M, and Zhang KYJ
- Subjects
- Acetylcholinesterase metabolism, Aged, Cholinesterase Inhibitors chemistry, Drug Discovery, Humans, Ligands, Molecular Structure, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, Tacrine chemistry, Tacrine pharmacology, Tacrine therapeutic use
- Abstract
Alzheimer's disease (AD) is one of the most common, progressive neurodegenerative disorders affecting the aged populations. Though various disease pathologies have been suggested for AD, the impairment of the cholinergic system is one of the critical factors for the disease progression. Restoration of the cholinergic transmission through acetylcholinesterase (AChE) inhibitors is a promising disease modifying therapy. Being the first marketed drug for AD, tacrine reversibly inhibits AChE and thereby slows the breakdown of the chemical messenger acetylcholine (ACh) in the brain. However, the atomic level of interactions of tacrine towards human AChE (hAChE) is unknown for years. Hence, in the current study, we report the X-ray structure of hAChE-tacrine complex at 2.85 Å resolution. The conformational heterogeneity of tacrine within the electron density was addressed with the help of molecular mechanics assisted methods and the low-energy ligand configuration is reported, which provides a mechanistic explanation for the high binding affinity of tacrine towards AChE. Additionally, structural comparison of reported hAChE structures sheds light on the conformational selection and induced fit effects of various active site residues upon binding to different ligands and provides insight for future drug design campaigns against AD where AChE is a drug target., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. A loss-of-function variant in SUV39H2 identified in autism-spectrum disorder causes altered H3K9 trimethylation and dysregulation of protocadherin β-cluster genes in the developing brain.
- Author
-
Balan S, Iwayama Y, Ohnishi T, Fukuda M, Shirai A, Yamada A, Weirich S, Schuhmacher MK, Dileep KV, Endo T, Hisano Y, Kotoshiba K, Toyota T, Otowa T, Kuwabara H, Tochigi M, Watanabe A, Ohba H, Maekawa M, Toyoshima M, Sasaki T, Nakamura K, Tsujii M, Matsuzaki H, Zhang KYJ, Jeltsch A, Shinkai Y, and Yoshikawa T
- Subjects
- Animals, Brain metabolism, Histone-Lysine N-Methyltransferase metabolism, Histones genetics, Histones metabolism, Mice, Protocadherins, Autistic Disorder, Histone-Lysine N-Methyltransferase genetics
- Abstract
Recent evidence has documented the potential roles of histone-modifying enzymes in autism-spectrum disorder (ASD). Aberrant histone H3 lysine 9 (H3K9) dimethylation resulting from genetic variants in histone methyltransferases is known for neurodevelopmental and behavioral anomalies. However, a systematic examination of H3K9 methylation dynamics in ASD is lacking. Here we resequenced nine genes for histone methyltransferases and demethylases involved in H3K9 methylation in individuals with ASD and healthy controls using targeted next-generation sequencing. We identified a novel rare variant (A211S) in the SUV39H2, which was predicted to be deleterious. The variant showed strongly reduced histone methyltransferase activity in vitro. In silico analysis showed that the variant destabilizes the hydrophobic core and allosterically affects the enzyme activity. The Suv39h2-KO mice displayed hyperactivity and reduced behavioral flexibility in learning the tasks that required complex behavioral adaptation, which is relevant for ASD. The Suv39h2 deficit evoked an elevated expression of a subset of protocadherin β (Pcdhb) cluster genes in the embryonic brain, which is attributable to the loss of H3K9 trimethylation (me3) at the gene promoters. Reduced H3K9me3 persisted in the cerebellum of Suv39h2-deficient mice to an adult stage. Congruently, reduced expression of SUV39H1 and SUV39H2 in the postmortem brain samples of ASD individuals was observed, underscoring the role of H3K9me3 deficiency in ASD etiology. The present study provides direct evidence for the role of SUV39H2 in ASD and suggests a molecular cascade of SUV39H2 dysfunction leading to H3K9me3 deficiency followed by an untimely, elevated expression of Pcdhb cluster genes during early neurodevelopment., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2021
- Full Text
- View/download PDF
13. Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
- Author
-
Chandran R and Dileep KV
- Subjects
- Amino Acid Sequence, Benzimidazoles pharmacology, Catalytic Domain, Enzyme Inhibitors pharmacology, Humans, Imidazolines pharmacology, Molecular Docking Simulation, Molecular Dynamics Simulation, Neuroprotective Agents pharmacology, Protein Binding, Protein Conformation, Pyrrolidonecarboxylic Acid chemistry, Structure-Activity Relationship, Alzheimer Disease drug therapy, Aminoacyltransferases antagonists & inhibitors, Amyloid beta-Peptides chemistry, Benzimidazoles chemistry, Enzyme Inhibitors chemistry, Imidazolines chemistry, Neuroprotective Agents chemistry
- Abstract
Secretory glutaminyl cyclase (sQC) plays an important role in the formation of the pyroglutamate-amyloid beta (pGlu-Aβ) peptide, one of the most abundant variants of Aβ found in the Alzheimer's disease (AD) brain. This post-translationally modified pGlu-Aβ possesses high toxicity and rapid aggregation propensity when compared to the wild-type Aβ (WT-Aβ). Since pGlu-Aβ acts as seed for WT-Aβ, the inhibition of sQC limits the formation of pGlu-Aβ and reduces the overall load of Aβ plaques in the AD brain. PQ912 is a potent inhibitor of sQC and has been enrolled in phase 2b clinical trial of the AD drug development pipeline; however, the binding mode of PQ912 against sQC is not elucidated yet. Understanding the binding mode of PQ912 is important as it helps in the discovery against AD where sQC as a target. To explore the binding mode of PQ912, we employed ensemble docking towards 9 sQC structures that differ either in active site geometry or in the bound ligands. Further pose clustering and binding energy calculations yielded three possible binding modes for PQ912. Finally, all atom molecular dynamics simulations determined the most energetically favorable binding mode for PQ912, in the active site of sQC, which is similar to that of LSB-09, a recently reported sQC inhibitor containing benzimidazole-6-carboxamide moiety., (© 2021 John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
14. Neuroprotective derivatives of tacrine that target NMDA receptor and acetyl cholinesterase - Design, synthesis and biological evaluation.
- Author
-
Remya C, Dileep KV, Koti Reddy E, Mantosh K, Lakshmi K, Sarah Jacob R, Sajith AM, Jayadevi Variyar E, Anwar S, Zhang KYJ, Sadasivan C, and Omkumar RV
- Abstract
The complex and multifactorial nature of neuropsychiatric diseases demands multi-target drugs that can intervene with various sub-pathologies underlying disease progression. Targeting the impairments in cholinergic and glutamatergic neurotransmissions with small molecules has been suggested as one of the potential disease-modifying approaches for Alzheimer's disease (AD). Tacrine, a potent inhibitor of acetylcholinesterase (AChE) is the first FDA approved drug for the treatment of AD. Tacrine is also a low affinity antagonist of N-methyl-D-aspartate receptor (NMDAR). However, tacrine was withdrawn from its clinical use later due to its hepatotoxicity. With an aim to develop novel high affinity multi-target directed ligands (MTDLs) against AChE and NMDAR, with reduced hepatotoxicity, we performed in silico structure-based modifications on tacrine, chemical synthesis of the derivatives and in vitro validation of their activities. Nineteen such derivatives showed inhibition with IC
50 values in the range of 18.53 ± 2.09 - 184.09 ± 19.23 nM against AChE and 0.27 ± 0.05 - 38.84 ± 9.64 μM against NMDAR. Some of the selected compounds also protected rat primary cortical neurons from glutamate induced excitotoxicity. Two of the tacrine derived MTDLs, 201 and 208 exhibited in vivo efficacy in rats by protecting against behavioral impairment induced by administration of the excitotoxic agent, monosodium glutamate. Additionally, several of these synthesized compounds also exhibited promising inhibitory activitiy against butyrylcholinesterase. MTDL-201 was also devoid of hepatotoxicity in vivo . Given the therapeutic potential of MTDLs in disease-modifying therapy, our studies revealed several promising MTDLs among which 201 appears to be a potential candidate for immediate preclinical evaluations., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. C.R., E.K.R., E.J.V., S.A., C.S. and R.V.O. are inventors of patent application containing data presented in this manuscript., (© 2021 The Authors.)- Published
- 2021
- Full Text
- View/download PDF
15. A multidimensional computational exploration of congenital myasthenic syndrome causing mutations in human choline acetyltransferase.
- Author
-
Janežič M, Dileep KV, and Zhang KYJ
- Subjects
- Acetylcholinesterase genetics, GPI-Linked Proteins chemistry, GPI-Linked Proteins genetics, Humans, Protein Structure, Secondary, Acetylcholinesterase chemistry, Computer Simulation, Mutation, Myasthenic Syndromes, Congenital genetics
- Abstract
Missense mutations of human choline acetyltransferase (CHAT) are mainly associated with congenital myasthenic syndrome (CMS). To date, several pathogenic mutations have been reported, but due to the rarity and genetic complexity of CMS and difficult genotype-phenotype correlations, the CHAT mutations, and their consequences are underexplored. In this study, we systematically sift through the available genetic data in search of previously unreported pathogenic mutations and use a dynamic in silico model to provide structural explanations for the pathogenicity of the reported deleterious and undetermined variants. Through rigorous multiparameter analyses, we conclude that mutations can affect CHAT through a variety of different mechanisms: by disrupting the secondary structure, by perturbing the P-loop through long-range allosteric interactions, by disrupting the domain connecting loop, and by affecting the phosphorylation process. This study provides the first dynamic look at how mutations affect the structure and catalytic activity in CHAT and highlights the need for further genomic research to better understand the pathology of CHAT., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
16. Targeting LIF/LIFR signaling in cancer.
- Author
-
Viswanadhapalli S, Dileep KV, Zhang KYJ, Nair HB, and Vadlamudi RK
- Abstract
Leukemia inhibitory factor (LIF), and its receptor (LIFR), are commonly over-expressed in many solid cancers and recent studies have implicated LIF/LIFR axis as a promising clinical target for cancer therapy. LIF/LIFR activate oncogenic signaling pathways including JAK/STAT3 as immediate effectors and MAPK, AKT, mTOR further downstream. LIF/LIFR signaling plays a key role in tumor growth, progression, metastasis, stemness and therapy resistance. Many solid cancers show overexpression of LIF and autocrine stimulation of the LIF/LIFR axis; these are associated with a poorer relapse-free survival. LIF/LIFR signaling also plays a role in modulating multiple immune cell types present in tumor micro environment (TME). Recently, two targeted agents that target LIF (humanized anti-LIF antibody, MSC-1) and LIFR inhibitor (EC359) were under development. Both agents showed effectivity in preclinical models and clinical trials using MSC-1 antibody are in progress. This article reviews the significance of LIF/LIFR pathways and inhibitors that disrupt this process for the treatment of cancer., (© 2021 Chongqing Medical University. Production and hosting by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
17. Chemical similarity assisted search for acetylcholinesterase inhibitors: Molecular modeling and evaluation of their neuroprotective properties.
- Author
-
Remya C, Dileep KV, Variyar EJ, Zhang KYJ, Omkumar RV, and Sadasivan C
- Subjects
- Acetylcholinesterase, Animals, Cells, Cultured, Cholinesterase Inhibitors chemistry, Computer Simulation, Databases, Chemical, Female, GPI-Linked Proteins antagonists & inhibitors, Glutamic Acid toxicity, HEK293 Cells, Humans, Molecular Docking Simulation, Molecular Dynamics Simulation, Neurons drug effects, Neurons metabolism, Neuroprotective Agents chemistry, Primary Cell Culture, Rats, Structure-Activity Relationship, Cholinesterase Inhibitors pharmacology, Neurons cytology, Neuroprotective Agents pharmacology
- Abstract
Alzheimer's disease (AD) is an obstinate and progressive neurodegenerative disorder, mainly characterized by cognitive decline. Increasing number of AD patients and the lack of promising treatment strategies demands novel therapeutic agents to combat various disease pathologies in AD. Recent progresses in understanding molecular mechanisms in AD helped researchers to streamline the various therapeutic approaches. Inhibiting acetylcholinesterase (AChE) activity has emerged as one of the potential treatment strategies. The present study discusses the identification of two potent AChE inhibitors (ZINC11709541 and ZINC11996936) from ZINC database through conventional in silico approaches and their in vitro validations. These inhibitors have strong preferences towards AChE than butyrylcholinesterase (BChE) and didn't evoke any significant reduction in the cell viability of HEK-293 cells and primary cortical neurons. Furthermore, promising neuroprotective properties has also been displayed against glutamate induced excitotoxicity in primary cortical neurons. The present study proposes two potential drug lead compounds for the treatment of AD, that can be used for further studies and preclinical evaluation., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
18. Piperidine-4-carboxamide as a new scaffold for designing secretory glutaminyl cyclase inhibitors.
- Author
-
Dileep KV, Sakai N, Ihara K, Kato-Murayama M, Nakata A, Ito A, Sivaraman DM, Shin JW, Yoshida M, Shirouzu M, and Zhang KYJ
- Subjects
- Alzheimer Disease drug therapy, Amyloid beta-Peptides metabolism, Brain drug effects, Brain metabolism, Cell Line, Tumor, Humans, Molecular Docking Simulation, Pyrrolidonecarboxylic Acid metabolism, Aminoacyltransferases antagonists & inhibitors, Piperidines pharmacology
- Abstract
Alzheimer's disease (AD), a common chronic neurodegenerative disease, has become a major public health concern. Despite years of research, therapeutics for AD are limited. Overexpression of secretory glutaminyl cyclase (sQC) in AD brain leads to the formation of a highly neurotoxic pyroglutamate variant of amyloid beta, pGlu-Aβ, which acts as a potential seed for the aggregation of full length Aβ. Preventing the formation of pGlu-Aβ through inhibition of sQC has become an attractive disease-modifying therapy in AD. In this current study, through a pharmacophore assisted high throughput virtual screening, we report a novel sQC inhibitor (Cpd-41) with a piperidine-4-carboxamide moiety (IC
50 = 34 μM). Systematic molecular docking, MD simulations and X-ray crystallographic analysis provided atomistic details of the binding of Cpd-41 in the active site of sQC. The unique mode of binding and moderate toxicity of Cpd-41 make this molecule an attractive candidate for designing high affinity sQC inhibitors., (Copyright © 2020 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
19. ATP7A Clinical Genetics Resource - A comprehensive clinically annotated database and resource for genetic variants in ATP7A gene.
- Author
-
Mhaske A, Dileep KV, Kumar M, Poojary M, Pandhare K, Zhang KYJ, Scaria V, and Binukumar BK
- Abstract
ATP7A is a critical copper transporter involved in Menkes Disease, Occipital horn Syndrome and X-linked distal spinal muscular atrophy type 3 which are X linked genetic disorders. These are rare diseases and their genetic epidemiology of the diseases is unknown. A number of genetic variants in the genes have been reported in published literature as well as databases, however, understanding the pathogenicity of variants and genetic epidemiology requires the data to be compiled in a unified format. To this end, we systematically compiled genetic variants from published literature and datasets. Each of the variants were systematically evaluated for evidences with respect to their pathogenicity and classified as per the American College of Medical Genetics and the Association of Molecular Pathologists (ACMG-AMP) guidelines into Pathogenic, Likely Pathogenic, Benign, Likely Benign and Variants of Uncertain Significance. Additional integrative analysis of population genomic datasets provides insights into the genetic epidemiology of the disease through estimation of carrier frequencies in global populations. To deliver a mechanistic explanation for the pathogenicity of selected variants, we also performed molecular modeling studies. Our modeling studies concluded that the small structural distortions observed in the local structures of the protein may lead to the destabilization of the global structure. To the best of our knowledge, ATP7A Clinical Genetics Resource is one of the most comprehensive compendium of variants in the gene providing clinically relevant annotations in gene., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2020 The Author(s).)
- Published
- 2020
- Full Text
- View/download PDF
20. EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling.
- Author
-
Yue X, Wu F, Wang J, Kim K, Santhamma B, Dileep KV, Zhang KYJ, Viswanadhapalli S, Vadlamudi RK, Ahmed G, Feng Z, Nickisch K, and Hu W
- Subjects
- Cell Line, Tumor, Cell Movement drug effects, Humans, Receptors, OSM-LIF metabolism, STAT3 Transcription Factor metabolism, Small Molecule Libraries chemistry, Leukemia Inhibitory Factor metabolism, Signal Transduction drug effects, Small Molecule Libraries pharmacology
- Published
- 2020
- Full Text
- View/download PDF
21. Structural characterization of Kannurin isoforms and evaluation of the role of β-hydroxy fatty acid tail length in functional specificity.
- Author
-
Shabeer Ali H, Ajesh K, Dileep KV, Prajosh P, and Sreejith K
- Subjects
- Anti-Infective Agents chemistry, Anti-Infective Agents pharmacology, Bacillus cereus chemistry, Bacillus cereus genetics, Fatty Acids genetics, Fungi drug effects, Fungi pathogenicity, Lipids genetics, Lipopeptides genetics, Micelles, Protein Isoforms chemistry, Protein Isoforms genetics, Fatty Acids chemistry, Lipids chemistry, Lipopeptides chemistry
- Abstract
The novel anti-fungal cyclic lipopeptide 'Kannurin' and its three structural variants produced by Bacillus cereus AK1 were previously reported from our laboratory. The present study reports unexplored structural variants of Kannurin those have functional benefits. Due to the difference in β-hydroxy fatty acid tail length, they are designated here as Kannurin A (m/z 994.67 ± 0.015), B (m/z 1008.68 ± 0.017), C (m/z 1022.69 ± 0.021), D (m/z 1036.70 ± 0.01), C
L (m/z 1040.71 ± 0.02) and DL (m/z 1054.72 ± 0.01). The isoform A (m/z 994.67 ± 0.015) is the shortest cyclic form of Kannurin identified so far. In addition, CL (m/z 1040.71 ± 0.02) and DL (m/z 1054.72 ± 0.01) are the rare natural linear forms. The results of the antimicrobial assays deduced that the difference in lipid tail length of the isoforms contributes tremendous differences in their antimicrobial properties. The isoforms with short lipid tails (A and B) are more selective and potent towards bacteria, whereas the isoforms with long lipid tails (C and D) are more potent against fungi. The molecular dynamics studies and electron microscopic observations supported with circular dichroic spectroscopy analysis showed the structural confirmation and formation of aggregates of Kannurin in solution. The molecular dynamics simulation studies revealed that a single molecule of Kannurin makes enormous intra-molecular interactions and structural re-arrangements to attain stable lowest energy state in solution. When they reach a particular concentration (CMC) especially in aqueous environment, tends to form structural aggregates called 'micelles'. With the structural information and activity relationship described in this study, it is trying to point out the sensitive structural entities that can be modified to improve the efficacy and target specificities of lipopeptide class of antibiotics.- Published
- 2020
- Full Text
- View/download PDF
22. Indole fragments for the design of lead molecules against pancreatitis.
- Author
-
Dileep KV, Ashok S, Remya C, Dharmendra KY, Pérez-Sánchez H, and Sadasivan C
- Subjects
- Binding Sites, Dose-Response Relationship, Drug, Humans, Molecular Docking Simulation, Molecular Dynamics Simulation, Pancreatitis drug therapy, Protein Binding, Spectrum Analysis, Structure-Activity Relationship, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents pharmacology, Drug Design, Indoles chemistry
- Abstract
Communicated by Ramaswamy H. Sarma.
- Published
- 2020
- Full Text
- View/download PDF
23. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
- Author
-
Nair HB, Santhamma B, Dileep KV, Binkley P, Acosta K, Zhang KYJ, Schenken R, and Nickisch K
- Subjects
- Animals, Contraceptive Agents, Female adverse effects, Contraceptive Agents, Female chemistry, Estrenes administration & dosage, Estrenes adverse effects, Female, Humans, Leiomyoma pathology, Mice, Molecular Docking Simulation, Molecular Structure, Norpregnadienes administration & dosage, Norpregnadienes adverse effects, Oximes administration & dosage, Oximes adverse effects, Progesterone Congeners adverse effects, Progesterone Congeners chemistry, Receptors, Progesterone chemistry, Receptors, Progesterone metabolism, Structure-Activity Relationship, Uterine Neoplasms pathology, Uterus drug effects, Uterus pathology, Xenograft Model Antitumor Assays, Cell Proliferation drug effects, Contraceptive Agents, Female administration & dosage, Leiomyoma drug therapy, Progesterone Congeners administration & dosage, Receptors, Progesterone agonists, Uterine Neoplasms drug therapy
- Abstract
Uterine fibroids (UFs) are associated with irregular or excessive uterine bleeding, pelvic pain or pressure, or infertility. Ovarian steroid hormones support the growth and maintenance of UFs. Ulipristal acetate (UPA) a selective progesterone receptor (PR) modulator (SPRM) reduce the size of UFs, inhibit ovulation and lead to amenorrhea. Recent liver toxicity concerns with UPA, diminished enthusiasm for its use and reinstate the critical need for a safe, efficacious SPRM to treat UFs. In the current study, we evaluated the efficacy of new SPRM, EC313, for the treatment for UFs using a NOD-SCID mouse model. EC313 treatment resulted in a dose-dependent reduction in the fibroid xenograft weight (p < 0.01). Estradiol (E2) induced proliferation was blocked significantly in EC313-treated xenograft fibroids (p < 0.0001). Uterine weight was reduced by EC313 treatment compared to UPA treatment. ER and PR were reduced in EC313-treated groups compared to controls (p < 0.001) and UPA treatments (p < 0.01). UF specific desmin and collagen were markedly reduced with EC313 treatment. The partial PR agonism and no signs of unopposed estrogenicity makes EC313 a candidate for the long-term treatment for UFs. Docking studies have provided a structure based explanation for the SPRM activity of EC313.
- Published
- 2019
- Full Text
- View/download PDF
24. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
- Author
-
Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, and Vadlamudi RK
- Subjects
- Cell Line, Tumor, Humans, Leukemia Inhibitory Factor, Leukemia Inhibitory Factor Receptor alpha Subunit, Receptors, OSM-LIF, Signal Transduction, Triple Negative Breast Neoplasms
- Abstract
Leukemia inhibitory factor receptor (LIFR) and its ligand LIF play a critical role in cancer progression, metastasis, stem cell maintenance, and therapy resistance. Here, we describe a rationally designed first-in-class inhibitor of LIFR, EC359, which directly interacts with LIFR to effectively block LIF/LIFR interactions. EC359 treatment exhibits antiproliferative effects, reduces invasiveness and stemness, and promotes apoptosis in triple-negative breast cancer (TNBC) cell lines. The activity of EC359 is dependent on LIF and LIFR expression, and treatment with EC359 attenuated the activation of LIF/LIFR-driven pathways, including STAT3, mTOR, and AKT. Concomitantly, EC359 was also effective in blocking signaling by other LIFR ligands (CTF1, CNTF, and OSM) that interact at LIF/LIFR interface. EC359 significantly reduced tumor progression in TNBC xenografts and patient-derived xenografts (PDX), and reduced proliferation in patient-derived primary TNBC explants. EC359 exhibits distinct pharmacologic advantages, including oral bioavailability, and in vivo stability. Collectively, these data support EC359 as a novel targeted therapeutic that inhibits LIFR oncogenic signaling. See related commentary by Shi et al., p. 1337 ., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
25. Crystal structure of phospholipase A 2 in complex with 1-naphthaleneacetic acid.
- Author
-
Dileep KV, Remya C, Tintu I, Mandal PK, Karthe P, Haridas M, and Sadasivan C
- Subjects
- Animals, Binding Sites, Catalytic Domain, Kinetics, Ligands, Models, Molecular, Protein Binding, Swine, Crystallography, X-Ray, Naphthaleneacetic Acids chemistry, Phospholipases A2 chemistry, Protein Conformation
- Abstract
Phospholipase A
2 (PLA2 ) is one of the rate limiting enzymes involved in the production of arachidonic acid, a potent inflammatory mediator. PLA2 is widely distributed all over the animal kingdom. It is also seen in inflammatory exudation and venoms of different organisms. The studies demonstrated that PLA2 inhibitors have broad spectrum activities that they can either be used against inflammation or envenomation. In this study, the inhibitory activity of 1-napthaleneacetic acid (NAA) against porcine pancreatic PLA2 has been explained through isothermal titration calorimetry and enzyme kinetics studies. The atomic level of interactions of NAA with PLA2 was also studied using X-ray crystallography. Apart from these findings, the theoretical binding affinities and mode of interactions of two naphthalene-based NSAIDs such as naproxen (NAP) and nabumetone (NAB) were studied through molecular modeling. The studies proved that the selected ligands are binding at the doorway of the active site cleft and hindering the substrate entry to the active site. The study brings out a potential scaffold for the designing of broad spectrum PLA2 inhibitors which can be used for inflammation or envenomation. © 2018 IUBMB Life, 70(10):995-1001, 2018., (© 2018 International Union of Biochemistry and Molecular Biology.)- Published
- 2018
- Full Text
- View/download PDF
26. Binding of acarbose, an anti-diabetic drug to lysozyme: a combined structural and thermodynamic study.
- Author
-
Dileep KV, Nithiyanandan K, and Remya C
- Subjects
- Circular Dichroism, Humans, Molecular Docking Simulation, Molecular Structure, Protein Binding, Thermodynamics, Acarbose chemistry, Acarbose pharmacology, Amyloidosis drug therapy, Drug Repositioning, Glycoside Hydrolase Inhibitors chemistry, Muramidase chemistry
- Published
- 2018
- Full Text
- View/download PDF
27. A comprehensive approach to ascertain the binding mode of curcumin with DNA.
- Author
-
Haris P, Mary V, Aparna P, Dileep KV, and Sudarsanakumar C
- Subjects
- Animals, Calorimetry, Calorimetry, Differential Scanning, Cattle, Curcumin chemistry, DNA chemistry, Models, Molecular, Nucleic Acid Denaturation, Spectrometry, Fluorescence, Spectrophotometry, Ultraviolet, Temperature, Curcumin metabolism, DNA metabolism
- Abstract
Curcumin is a natural phytochemical from the rhizoma of Curcuma longa, the popular Indian spice that exhibits a wide range of pharmacological properties like antioxidant, anticancer, anti-inflammatory, antitumor, and antiviral activities. In the published literatures we can see different studies and arguments on the interaction of curcumin with DNA. The intercalative binding, groove binding and no binding of curcumin with DNA were reported. In this context, we conducted a detailed study to understand the mechanism of recognition of dimethylsulfoxide-solubilized curcumin by DNA. The interaction of curcumin with calf thymus DNA (ctDNA) was confirmed by agarose gel electrophoresis. The nature of binding and energetics of interaction were studied by Isothermal Titration Calorimetry (ITC), Differential Scanning Calorimetry (DSC), UV-visible, fluorescence and melting temperature (T
m ) analysis. The experimental data were compared with molecular modeling studies. Our investigation confirmed that dimethylsulfoxide-solubilized curcumin binds in the minor groove of the ctDNA without causing significant structural alteration to the DNA., (Copyright © 2016 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
28. Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo.
- Author
-
Nair HB, Santhamma B, Krishnegowda NK, Dileep KV, and Nickisch KJ
- Subjects
- Animals, Apoptosis drug effects, Breast drug effects, Breast metabolism, Breast pathology, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cell Line, Tumor, Cell Proliferation drug effects, Drug Discovery, Estradiol pharmacology, Estrogens pharmacology, Female, Humans, Menopause drug effects, Mice, Mice, Inbred C57BL, Breast Neoplasms prevention & control, Estradiol therapeutic use, Estrogens therapeutic use, Hormone Replacement Therapy methods, Receptors, Progesterone metabolism
- Abstract
Use of estrogen or estrogen/progestin combination was an approved regimen for menopausal hormonal therapy (MHT). However, more recent patient-centered studies revealed an increase in the incidence of breast cancer in women receiving menopausal hormone therapy with estrogen plus progestin rather than estrogen alone. Tissue selective estrogen complex (TSEC) has been proposed to eliminate the progesterone component of MHT with supporting evidences. Based on our previous studies it is evident that SPRMs have a safer profile on endometrium in preventing unopposed estrogenicity. We hypothesized that a combination of estradiol (E2) with selective progesterone receptor modulator (SPRM) to exert a safer profile on endometrium will also reduce mammary gland proliferation and could be used to prevent breast cancer when used in MHT. In order to test our hypothesis, we compared the estradiol alone or in combination with our novel SPRMs, EC312 and EC313. The compounds were effectively controlled E2 mediated cell proliferation and induced apoptosis in T47D breast cancer cells. The observed effects were found comparable that of BZD in vitro. The effects of SPRMs were confirmed by receptor binding studies as well as gene and protein expression studies. Proliferation markers were found downregulated with EC312/313 treatment in vitro and reduced E2 induced mammary gland proliferation, evidenced as reduced ductal branching and terminal end bud growth in vivo. These data supporting our hypothesis that E2+EC312/EC313 blocked the estrogen action may provide basic rationale to further test the clinical efficacy of SPRMs to prevent breast cancer incidence in postmenopausal women undergoing MHT.
- Published
- 2016
- Full Text
- View/download PDF
29. Rational design and interaction studies of combilexins towards duplex DNA.
- Author
-
Dileep KV, Vijeesh V, and Remya C
- Subjects
- Calorimetry, Molecular Docking Simulation, Thermodynamics, 2,4-Dichlorophenoxyacetic Acid chemistry, DNA chemistry, Drug Design, Tacrine chemistry
- Abstract
DNA, which is the genetic material, plays a predominant role in all living organisms. Alterations in the structure and function of this genetic material correlate with complex diseases such as cancer. A number of anticancer drugs exert their action by binding to DNA. Although DNA binding compounds exert genotoxicity, there is a high demand for novel DNA binding molecules because they can be further developed into anticancer drugs. In the present study, the mode of interaction of two compounds, 2,4-D and tacrine, has been determined to be minor groove binding and intercalation, respectively. Subsequently, from their binding modes, novel combilexin molecules were designed using computational tools and their mode of binding and affinities towards DNA were determined through a series of molecular modeling experiments such as molecular docking, molecular dynamics and binding free energy calculations. The entire study focuses on the potential effects of combilexins compared to intercalators and minor groove binders. The combilexins deduced from the current study may be considered as lead compounds for the development of better anticancer drugs.
- Published
- 2016
- Full Text
- View/download PDF
30. Comparative studies on the inhibitory activities of selected benzoic acid derivatives against secretory phospholipase A2, a key enzyme involved in the inflammatory pathway.
- Author
-
Dileep KV, Remya C, Cerezo J, Fassihi A, Pérez-Sánchez H, and Sadasivan C
- Subjects
- Catalytic Domain, Humans, Hydrophobic and Hydrophilic Interactions, Kinetics, Molecular Docking Simulation, Molecular Dynamics Simulation, Phospholipases A2, Secretory antagonists & inhibitors, Titrimetry, Anti-Inflammatory Agents chemistry, Benzoates chemistry, Phospholipases A2, Secretory chemistry
- Abstract
Inflammation is considered to be a key factor in major diseases like cancer, Alzheimer's disease, Parkinson's disease, etc. For the past few decades, pharmaceutical companies have explored new effective medications against inflammation. As a part of their detailed studies, many drug targets and drugs have been introduced against inflammation. In the present study, the inhibiting capacities of selected benzoic acid derivatives like gallic acid, vannilic acid, syringic acid and protocatechuic acid against secretory phospholipase A2 (sPLA2), a major enzyme involved in the inflammatory pathway, have been investigated. The detailed in vitro, biophysical and in silico studies carried out on these benzoic acid derivatives revealed that all the selected compounds have a uniform mode of binding in the active site of sPLA2 and are inhibitory in micromolar concentrations. The study also focuses on the non-selective inhibitory activity of an NSAID, aspirin, against sPLA2.
- Published
- 2015
- Full Text
- View/download PDF
31. Derivatives form better lipoxygenase inhibitors than piperine: in vitro and in silico study.
- Author
-
Tomy MJ, Sharanya CS, Dileep KV, Prasanth S, Sabu A, Sadasivan C, and Haridas M
- Subjects
- Alkaloids chemistry, Benzaldehydes chemistry, Benzoates chemistry, Benzodioxoles chemistry, Catalytic Domain drug effects, Computer Simulation, Fatty Acids, Unsaturated chemistry, Humans, Lipoxygenase chemistry, Lipoxygenase metabolism, Lipoxygenase Inhibitors chemistry, Models, Molecular, Piper nigrum chemistry, Piperidines chemistry, Polyunsaturated Alkamides chemistry, Protein Binding, Glycine max enzymology, Alkaloids pharmacology, Benzaldehydes pharmacology, Benzoates pharmacology, Benzodioxoles pharmacology, Fatty Acids, Unsaturated pharmacology, Lipoxygenase Inhibitors pharmacology, Piperidines pharmacology, Polyunsaturated Alkamides pharmacology
- Abstract
Piperine is a secondary metabolite of black pepper. Its uses in medicine were already studied. However, its derivatives have not gained considerable attention. In the presented study, the Lipoxygenase (LOX) inhibitory activity of piperine and its derivatives, piperonylic acid, piperic acid, and piperonal have been assessed and compared by enzyme kinetics, ITC and molecular modeling experiments. The presented investigations expressed that all the studied compounds inhibited LOX by binding at its active site. The IC(50) values of these compounds were deduced from the kinetics data and found to be 85.79, 43.065, 45.17, and 50.78 μm for piperine, piperonylic acid, piperic acid, and piperonal, respectively. The binding free energies obtained from ITC experiments were -7.47, -8.33, -8.09, and -7.86 kcal/mol for piperine, piperonylic acid, piperic acid, and piperonal, respectively. Similarly, the glide scores obtained for piperine, piperonylic acid, piperic acid, and piperonal were -7.28, -10.32, -10.72, and -9.57 kcal/mol, respectively. The results of ITC and molecular modeling experiments suggested that piperonylic acid and piperonal exhibit stronger binding at the active site than piperine does. From the presented studies, it could be concluded that derivatives of piperine may be of higher significance than piperine for certain medicinal applications, implicating (Ayurvedic) fermented herbal drugs with piperine in them., (© 2014 John Wiley & Sons A/S.)
- Published
- 2015
- Full Text
- View/download PDF
32. TRAIL-based tumor sensitizing galactoxyloglucan, a novel entity for targeting apoptotic machinery.
- Author
-
Aravind SR, Joseph MM, George SK, Dileep KV, Varghese S, Rose-James A, Balaram P, Sadasivan C, and Sreelekha TT
- Subjects
- Annexin A5 metabolism, Apoptosis Regulatory Proteins, Caspases metabolism, Cell Line, Tumor, Cell Membrane Permeability drug effects, Cell Shape drug effects, Cell Size drug effects, Chromatin drug effects, Chromatin metabolism, Flow Cytometry, Fluorescent Dyes metabolism, Gene Expression Regulation, Neoplastic drug effects, Humans, Molecular Docking Simulation, Oligonucleotide Array Sequence Analysis, Propidium metabolism, Real-Time Polymerase Chain Reaction, Reproducibility of Results, Spectrometry, Fluorescence, Staining and Labeling, Apoptosis drug effects, Glucans pharmacology, TNF-Related Apoptosis-Inducing Ligand pharmacology
- Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an attractive target for cancer therapy due to its ability to selectively induce apoptosis in cancer cells, without causing significant toxicity in normal tissues. We previously reported that galactoxyloglucan (PST001) possesses significant antitumor and immunomodulatory properties. However, the exact mechanism in mediating this anticancer effect is unknown. This study, for the first time, indicated that PST001 sensitizes non-small cell lung cancer (A549) and nasopharyngeal (KB) cells to TRAIL-mediated apoptosis. In vitro studies suggested that PST001 induced apoptosis primarily via death receptors and predominantly activated caspases belonging to the extrinsic apoptotic cascade. Microarray profiling of PST001 treated A549 and KB cells showed the suppression of survivin (BIRC5) and anti-apoptotic Bcl-2, as well as increased cytochrome C. TaqMan low density array analysis of A549 cells also confirmed that the induction of apoptosis by the polysaccharide occurred through the TRAIL-DR4/DR5 pathways. This was finally confirmed by in silico analysis, which revealed that PST001 binds to TRAIL-DR4/DR5 complexes more strongly than TNF and Fas ligand-receptor complexes. In summary, our results suggest the potential of PST001 to be developed as an anticancer agent that not only preserves innate biological activity of TRAIL, but also sensitizes cancer cells to TRAIL-mediated apoptosis., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
33. Flavanone glycosides as acetylcholinesterase inhibitors: computational and experimental evidence.
- Author
-
Remya C, Dileep KV, Tintu I, Variyar EJ, and Sadasivan C
- Abstract
Acetylcholinesterase hydrolyzes the neurotransmitter called acetylcholine and is crucially involved in the regulation of neurotransmission. One of the observable facts in the neurodegenerative disorders like Alzheimer's disease is the decrease in the level of acetylcholine. Available drugs that are used for the treatment of Alzheimer's disease are primarily acetylcholinesterase inhibitors with multiple activities. They maintain the level of acetylcholine in the brain by inhibiting the acetylcholinesterase function. Hence acetylcholinesterase inhibitors can be used as lead compounds for the development of drugs against AD. In the present study, the binding potential of four flavanone glycosides such as naringin, hesperidin, poncirin and sakuranin against acetylcholinesterase was analysed by using the method of molecular modeling and docking. The activity of the top scored compound, naringin was further investigated by enzyme inhibition studies and its inhibitory concentration (IC50) towards acetylcholinesterase was also determined.
- Published
- 2014
34. Cuminaldehyde as a lipoxygenase inhibitor: in vitro and in silico validation.
- Author
-
Tomy MJ, Dileep KV, Prasanth S, Preethidan DS, Sabu A, Sadasivan C, and Haridas M
- Subjects
- Cymenes, Humans, Arachidonate 15-Lipoxygenase chemistry, Benzaldehydes chemistry, Benzaldehydes isolation & purification, Cuminum chemistry, Lipoxygenase Inhibitors chemistry, Lipoxygenase Inhibitors isolation & purification, Models, Chemical, Plant Proteins antagonists & inhibitors, Plant Proteins chemistry, Glycine max enzymology
- Abstract
The search for lipoxygenase (LOX) inhibitors has been carried out for decades due to its importance in inflammatory diseases. In the present study, it was observed that the methanolic extract of Cuminum cyminum L. inhibited LOX activity. Activity-guided screening of the C. cyminum crude extracts helped the identification and isolation of cuminaldehyde as a 15-LOX inhibitor. The enzyme kinetics analysis suggested cuminaldehyde to be a competitive inhibitor and the IC 50 value derived from LB plots is 1,370 μM. Binding constants of cuminaldehyde on LOX was deduced by isothermal titration calorimetry. The combined thermodynamics and molecular modeling analyses suggested cuminaldehyde as a competitive LOX inhibitor. It is proposed from the present study that the coordinate bond between the Fe(2+) atom in the active site of the enzyme and the cuminaldehyde may be responsible for the enzyme inhibition. The study suggests that cuminaldehyde may be acting as an anti-inflammatory compound and may be therefore included in the category of leads for developing dual COX-LOX inhibitors as non-steroidal anti-inflammatory drugs (NSAIDs).
- Published
- 2014
- Full Text
- View/download PDF
35. A lectin from Spatholobus parviflorus inhibits Aspergillus flavus α-amylase: enzyme kinetics and thermodynamic studies.
- Author
-
Tintu I, Abhilash J, Dileep KV, Augustine A, Haridas M, and Sadasivan C
- Subjects
- Antifungal Agents chemistry, Antifungal Agents isolation & purification, Aspergillosis drug therapy, Aspergillus flavus drug effects, Humans, Kinetics, Molecular Docking Simulation, Plant Lectins chemistry, Plant Lectins isolation & purification, Thermodynamics, alpha-Amylases chemistry, alpha-Amylases metabolism, Antifungal Agents pharmacology, Aspergillus flavus enzymology, Fabaceae chemistry, Plant Lectins pharmacology, alpha-Amylases antagonists & inhibitors
- Abstract
Aspergillus flavus is a commonly found fungal pathogen which produces structurally related and highly toxic secondary metabolites, aflatoxins. It has been proposed that α-amylase inhibitors may limit the ability of the fungus to produce aflatoxins. Hence, this enzyme is a potent target for the development of antifungal agents. In this study, it was found that Spatholobus parviflorus seed lectin (SPL) can inhibit the growth of A. flavus with a MIC value of 1.5 mg/mL. The enzyme kinetics, molecular modeling and isothermal titration calorimetric studies suggest that SPL can inhibit α-amylase with Ki value of 0.0042 mm. Hence, it is suggested that the antifungal activity of SPL might be partly due to its ability to inhibit the enzyme α-amylase., (© 2014 John Wiley & Sons A/S.)
- Published
- 2014
- Full Text
- View/download PDF
36. Interactions of selected indole derivatives with COX-2 and their in silico structure modifications towards the development of novel NSAIDs.
- Author
-
Dileep KV, Remya C, Tintu I, and Sadasivan C
- Subjects
- Computer Simulation, Cyclooxygenase 1 metabolism, Drug Design, Molecular Docking Simulation, Molecular Dynamics Simulation, Cyclooxygenase 2 metabolism, Cyclooxygenase 2 Inhibitors chemistry, Indoles chemistry
- Abstract
Cyclooxygenase-2 (COX-2) is an important enzyme responsible for the formation of potent inflammatory mediators like prostaglandins, prostacyclin and thromboxane. Hence, inhibition of COX-2 is one of the best ways to control the inflammation. Non-steroidal anti-inflammatory drugs can control inflammation by inhibiting Cyclooxygenase. Selective inhibition of COX-2 is preferable over the inhibition of COX-1 because of the fewer adverse effects produced. Molecular modeling and docking of 134 selected indole compounds were done against COX-2. The pharmacophore-based in silico structural modifications of the best scored compounds were carried out in order to enhance the binding affinity and selectivity. The modification resulted in derivatives with better binding energies than that of known COX-2 inhibitors. The four best derivatives in terms of the binding energies were selected and their binding stabilities were studied by molecular dynamics simulation methods.
- Published
- 2014
- Full Text
- View/download PDF
37. Metal ions in sugar binding, sugar specificity and structural stability of Spatholobus parviflorus seed lectin.
- Author
-
Abhilash J, Dileep KV, Palanimuthu M, Geethanandan K, Sadasivan C, and Haridas M
- Subjects
- Agglutination, Binding Sites, Calorimetry, Cations, Divalent, Fabaceae chemistry, Molecular Docking Simulation, Molecular Dynamics Simulation, Protein Binding, Protein Multimerization, Protein Stability, Protein Structure, Quaternary, Seeds chemistry, Thermodynamics, Acetylgalactosamine chemistry, Calcium chemistry, Coordination Complexes chemistry, Galactose chemistry, Lactose chemistry, Manganese chemistry, Plant Lectins chemistry
- Abstract
Spatholobus parviflorus seed lectin (SPL) is a heterotetrameric lectin, with two α and two β monomers. In the crystal structure of SPL α monomer, two residues at positions 240 and 241 are missing. This region was modeled based on the positional and sequence similarities. The role of metal ions in SPL structure was analyzed by 10 ns molecular dynamics simulation. MD simulations were performed in the presence and absence of metal ions to explain the loss of haemagglutinating property of the lectin due to demetallization. Demetallized structure was found to deviate drastically at the metal binding loop region. Affinity of different sugars like N-acetyl galactosamine (GalNAc), D-galactose and lactose towards the native and demetallized protein was calculated by molecular docking studies. It was found that the sugar binding site got severely distorted in demetallized lectin. Consequently, sugar binding ability of lectin might be decreasing in the demetallized condition. Isothermal titration calorimetric (ITC) analysis of the sugars in the presence of native and demetallized protein confirmed the in silico results. It was observed after molecular dynamics simulations, that significant structural deviations were not caused in the quaternary structure of demetallized lectin. It was confirmed that the structural changes modified the sugar binding ability, as well as sugar specificity of the present lectin. The role of metal ions in sugar binding is described based on the in silico studies and ITC analysis. A comprehensive analysis of the ITC data suggests that the sugar specificity of the metal bound lectin and the loss of sugar specificity due to metal chelation are not linear.
- Published
- 2013
- Full Text
- View/download PDF
38. Interactions of selected indole derivatives with phospholipase A₂: in silico and in vitro analysis.
- Author
-
Dileep KV, Remya C, Tintu I, Haridas M, and Sadasivan C
- Subjects
- Animals, Binding Sites, Humans, Isoenzymes antagonists & inhibitors, Isoenzymes chemistry, Kinetics, Molecular Docking Simulation, Pancreas chemistry, Pancreas enzymology, Phospholipase A2 Inhibitors, Protein Binding, Swine, Thermodynamics, Anti-Inflammatory Agents chemistry, Enzyme Inhibitors chemistry, Indoleacetic Acids chemistry, Indoles chemistry, Phospholipases A2 chemistry
- Abstract
Phospholipase A2 (PLA₂) is one of the key enzymes involved in the formation of inflammatory mediators. Inhibition of PLA₂ is considered to be one of the efficient methods to control inflammation. In silico docking studies of 160 selected indole derivatives performed against porcine pancreatic PLA₂ (ppsPLA2) suggested that, CID2324681, CID8617 (indolebutyric acid or IBA), CID22097771 and CID802 (indoleacetic acid or IAA) exhibited highest binding energies. In silico analysis was carried out to predict some of the ADME properties. The binding potential of these compounds with human non pancreatic secretory PLA₂ (hnpsPLA₂) was determined using molecular docking studies. In order to corroborate the in silico results, enzyme kinetics and isothermal titration calorimetric analysis of the two selected compounds, IAA and IBA were performed against ppsPLA₂. From the analysis, it was concluded that IAA and IBA can act as competitive inhibitors to the enzyme and may be used as anti inflammatory agents.
- Published
- 2013
- Full Text
- View/download PDF
39. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
- Author
-
Bhaskaran S, Dileep KV, Deepa SS, Sadasivan C, Klausner M, Krishnegowda NK, Tekmal RR, VandeBerg JL, and Nair HB
- Subjects
- Animals, Cell Cycle drug effects, Cell Line, Tumor, Cell Movement drug effects, Cyclin-Dependent Kinase 4 chemistry, Cyclin-Dependent Kinase 4 metabolism, Disease Models, Animal, Female, Flavonoids chemistry, Flavonoids toxicity, Humans, MAP Kinase Signaling System drug effects, Melanoma genetics, Melanoma metabolism, Melanoma pathology, Mice, Molecular Docking Simulation, Mutation, Protein Binding, Proto-Oncogene Proteins B-raf chemistry, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins B-raf metabolism, Transplantation, Heterologous, Tumor Burden drug effects, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Flavonoids pharmacology, Proto-Oncogene Proteins B-raf antagonists & inhibitors
- Abstract
Mutation in the BRAF gene (BRAFV600E) exists in nearly 70% of human melanomas. Targeted therapy against BRAFV600E kinase using a recently identified RAF-selective inhibitor, PLX4032, has been successful in early clinical trials. However, in patients with the normal BRAF allele (wild-type), PLX4032 is protumorigenic. This conundrum identifies the unmet need for novel therapeutic agents to target BRAFV600E kinase that are not counterproductive. We have identified gossypin, a pentahydroxy flavone, as a potent antimelanoma agent. Gossypin inhibited human melanoma cell proliferation, in vitro, in melanoma cell lines that harbor both BRAFV600E kinase and cyclin-dependent kinase 4 (CDK4) as well as in cells with BRAF wild-type allele. Gossypin inhibited kinase activities of BRAFV600E and CDK4, in vitro, possibly through direct binding of gossypin with these kinases, as confirmed by molecular docking studies. For cells harboring the BRAFV600E, gossypin inhibited cell proliferation through abrogation of the MEK-ERK-cyclin D1 pathway and in cells with BRAF wild-type allele, through attenuation of the retinoblastoma-cyclin D1 pathway. Furthermore, gossypin significantly inhibited melanoma growth in an organotypic three-dimensional skin culture mimicking human skin. Gossypin (10 and 100 mg/kg) treatment for 10 days in human melanoma (A375) cell xenograft tumors harboring BRAFV600E significantly reduced tumor volume through induction of apoptosis and increased survival rate in mice, and the effect was significantly superior to that of PLX4032 (10 mg/kg) or roscovitine 10 mg/kg. In summary, this study identified gossypin as a novel agent with dual inhibitory effects for BRAFV600E kinase and CDK4 for treatment of melanoma.
- Published
- 2013
- Full Text
- View/download PDF
40. In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile.
- Author
-
Remya C, Dileep KV, Tintu I, Variyar EJ, and Sadasivan C
- Subjects
- Acetylcholine metabolism, Alzheimer Disease drug therapy, Antioxidants chemistry, Antioxidants metabolism, Blood-Brain Barrier drug effects, Humans, Larrea, Oxidative Stress drug effects, Plant Preparations analogs & derivatives, Acetylcholinesterase metabolism, Cholinesterase Inhibitors chemistry, Cholinesterase Inhibitors metabolism, Masoprocol analogs & derivatives, Masoprocol chemistry, Masoprocol metabolism
- Abstract
Acetylcholinesterase (AChE) inhibitors are currently in focus for the pharmacotherapy of Alzheimer's disease (AD). These inhibitors increase the level of acetylcholine in the brain and facilitate cholinergic neurotransmission. AChE inhibitors such as rivastigmine, galantamine, physostigmine and huperzine are obtained from plants, indicating that plants can serve as a potential source for novel AChE inhibitors. We have performed a virtual screening of diverse natural products with distinct chemical structure against AChE. NDGA was one among the top scored compounds and was selected for enzyme kinetic studies. The IC(50) of NDGA on AChE was 46.2 μM. However, NDGA showed very poor central nervous system (CNS) activity and blood-brain barrier (BBB) penetration. In silico structural modification on NDGA was carried out in order to obtain derivatives with better CNS activity as well as BBB penetration. The studies revealed that some of the designed compounds can be used as lead molecules for the development of drugs against AD.
- Published
- 2013
- Full Text
- View/download PDF
41. An isoquinoline alkaloid, berberine, can inhibit fungal alpha amylase: enzyme kinetic and molecular modeling studies.
- Author
-
Tintu I, Dileep KV, Augustine A, and Sadasivan C
- Subjects
- Aspergillosis drug therapy, Aspergillosis enzymology, Aspergillus flavus growth & development, Humans, Kinetics, Molecular Dynamics Simulation, alpha-Amylases metabolism, Antifungal Agents pharmacology, Aspergillus flavus drug effects, Aspergillus flavus enzymology, Berberine pharmacology, alpha-Amylases antagonists & inhibitors
- Abstract
Aspergillus flavus is a commonly found fungal pathogen, which produces aflatoxins, highly toxic and hepatocarcinogenic natural compounds. Inhibition of fungal alpha amylase activity has been found to limit the ability of the fungus to produce aflatoxins. Berberine, an isoquinoline alkaloid commonly found in many medicinal plants, was identified to inhibit the growth of A. flavus. The amount of berberine required to inhibit the fungal mycelial growth was determined. The compound was also found to inhibit the alpha amylase from the A. flavus. The binding affinity of the compound toward alpha amylase and the enzyme inhibitory activity have been determined by enzyme kinetic studies and Isothermal Titration Calorimetric analysis. Molecular modeling and docking studies were carried out to understand the enzyme-ligand interactions., (© 2012 John Wiley & Sons A/S.)
- Published
- 2012
- Full Text
- View/download PDF
42. Anti-inflammatory property of n-hexadecanoic acid: structural evidence and kinetic assessment.
- Author
-
Aparna V, Dileep KV, Mandal PK, Karthe P, Sadasivan C, and Haridas M
- Subjects
- Animals, Anti-Inflammatory Agents chemistry, Catalytic Domain, Crystallography, Kinetics, Models, Molecular, Palmitic Acid chemistry, Phospholipases A2 chemistry, Phospholipases A2 metabolism, Protein Binding, Swine, Anti-Inflammatory Agents pharmacology, Palmitic Acid pharmacology, Phospholipase A2 Inhibitors
- Abstract
Ester bond hydrolysis of membrane phospholipids by Phospholipase A(2) and consequent release of fatty acids are the initiating steps of inflammation. It is proposed in this study that the inhibition of phospholipase A(2) is one of the ways to control inflammation. Investigations are carried out to identify the mode of inhibition of phospholipase A(2) by the n-hexadecanoic acid. It may help in designing of specific inhibitors of phospholipase A(2) as anti-inflammatory agents. The enzyme kinetics study proved that n-hexadecanoic acid inhibits phospholipase A(2) in a competitive manner. It was identified from the crystal structure at 2.5 Å resolution that the position of n-hexadecanoic acid is in the active site of the phospholipase A(2). The binding constant and binding energy have also been calculated using Isothermal Titration Calorimetry. Also, the binding energy of n-hexadecanoic acid to phospholipase A(2) was calculated by in silico method and compared with known inhibitors. It may be concluded from the structural and kinetics studies that the fatty acid, n-hexadecanoic acid, is an inhibitor of phospholipase A(2), hence, an anti-inflammatory compound. The inferences from the present study validate the rigorous use of medicated oils rich in n-hexadecanoic acid for the treatment of rheumatic symptoms in the traditional medical system of India, Ayurveda., (© 2012 John Wiley & Sons A/S.)
- Published
- 2012
- Full Text
- View/download PDF
43. Binding to PLA2 may contribute to the anti-inflammatory activity of catechol.
- Author
-
Dileep KV, Tintu I, Mandal PK, Karthe P, Haridas M, and Sadasivan C
- Subjects
- Binding Sites, Catalytic Domain, Catechols pharmacology, Computer Simulation, Crystallography, X-Ray, Kinetics, Phospholipases A2 chemistry, Phospholipases A2 metabolism, Protein Binding drug effects, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents pharmacology, Catechols chemistry, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology, Phospholipase A2 Inhibitors
- Abstract
Inhibiting PLA(2) activity should, in theory, be an effective approach to control the inflammation. Several naturally occurring polyphenolic compounds have been reported as inhibitors of PLA(2) . Among the naturally occurring polyphenols, catechol (1,2-dihydroxybenzene) possesses anti-inflammatory activity. Catechol can inhibit cyclooxygenase and lipo-oxygenase. By means of enzyme kinetic study, it was revealed that catechol can inhibit PLA(2) also. Crystal structure showed that catechol binds to PLA(2) at the opening of the active site cleft. This might stop the entry of substrate into the active site. Hence, catechol can be used as a lead compound for the development of novel anti-inflammatory drugs with PLA(2) as the target., (© 2011 John Wiley & Sons A/S.)
- Published
- 2012
- Full Text
- View/download PDF
44. Molecular docking studies of curcumin analogs with phospholipase A2.
- Author
-
Dileep KV, Tintu I, and Sadasivan C
- Subjects
- Animals, Catalytic Domain, Ligands, Molecular Dynamics Simulation, Protein Binding, Sus scrofa, Thermodynamics, Curcumin analogs & derivatives, Curcumin chemistry, Models, Molecular, Phospholipases A2 chemistry
- Abstract
The enzyme phospholipase A2 is responsible for the hydrolysis of membrane phospholipids that release arachidonic acid, which serves as a substrate for pro-inflammatory mediators, such as prostaglandins and leucotriens. The binding of the substrate to PLA2 occurs through a well-formed hydrophobic channel. So blocking the hydrophobic channel is an effective way to inhibit PLA2. Compounds inhibiting PLA2 have been implicated as potential therapeutic agents in the treatment of inflammation related diseases. Curcumin is a well studied compound isolated from the plant Curcuma longa. The PLA2 inhibiting activity of curcumin has been studied in our laboratory. The present study focuses whether any of the curcumin analogs can bind PLA2 more strongly than curcumin. To check this, binding of twenty eight different curcumin analogs to PLA2 have been studied by molecular modeling and docking. The mode of interactions of compounds with strong binding are discussed and reported here. It has been observed that four analogs namely rosmarinic acid, tetrahydrocurcumin, dihydrocurucmin and hexahydrocurcumin possess better binding energy than curcumin. The present study may lead to the better understanding of PLA2 inhibition by curcumin analogs. This may help to develop better anti-inflammatory drugs.
- Published
- 2011
- Full Text
- View/download PDF
45. Inhibition of beta-lactamase by 1,4-naphthalenedione from the plant Holoptelea integrifolia.
- Author
-
Vinod NV, Shijina R, Dileep KV, and Sadasivan C
- Subjects
- Amoxicillin pharmacology, Catalytic Domain, Enzyme Assays, Gas Chromatography-Mass Spectrometry, Hydrogen Bonding drug effects, Ligands, Naphthoquinones chemistry, Spectroscopy, Fourier Transform Infrared, Substrate Specificity drug effects, beta-Lactamases chemistry, Naphthoquinones isolation & purification, Naphthoquinones pharmacology, Ulmaceae chemistry, beta-Lactamase Inhibitors
- Abstract
The most important mechanism of the beta-lactam antibiotic resistance is the destruction of the antibiotics by the enzyme beta-lactamase. Use of beta-lactamase inhibitors in combination with antibiotics is one of the successful antibacterial strategies. The inhibitory effect of a phytochemical, 1,4-naphthalenedione, isolated from the plant Holoptelea integrifolia on beta-lactamase is reported here. This compound was found to have a synergistic effect with the antibiotic amoxicillin against a resistant strain of Staphylococcus aureus. The enzyme was purified from the organism and incubated with the compound. An assay showed that the compound can inhibit the enzymatic activity of beta-lactamase. Modeling and molecular docking studies indicated that the compound can fit into the active site of beta-lactamase. Hence, the compound can serve as a potential lead compound for the development of effective beta-lactamase inhibitor that can be used against beta-lactam-resistant microbial strains.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.